Suppr超能文献

连花清瘟胶囊抑制非致死剂量流感病毒诱导的小鼠金黄色葡萄球菌二次感染。

Lianhuaqingwen capsule inhibits non-lethal doses of influenza virus-induced secondary Staphylococcus aureus infection in mice.

机构信息

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

出版信息

J Ethnopharmacol. 2022 Nov 15;298:115653. doi: 10.1016/j.jep.2022.115653. Epub 2022 Aug 19.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Lianhuaqingwen capsule (LH-C) is a traditional Chinese medicine (TCM), consisting of two prescriptions, Ma-xing-shi-gan-tang (MXSGT) and Yinqiao San. It has been proven to have antiviral, antibacterial, and immunomodulatory effects in recent years. Clinically, it is commonly used in the treatment of respiratory tract infections.

AIM OF THE STUDY

It was demonstrated in our previous studies that LH-C has an effect of antivirus and inhibits influenza virus-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules in vitro. However, LH-C's effect against influenza-induced secondary bacterial infection in animal studies remains unclear. Therefore, in the present study, we established a mouse model of infection with non-lethal doses of influenza virus(H1N1) and secondary infection of Staphylococcus aureus (S. aureus), to investigate the potential effects of LH-C.

METHODS

Experiments were carried out on BALB/c mice infecting non-lethal doses of H1N1 and non-lethal doses of S. aureus, and the viral, and bacterial doses were determined by observing and recording changes in the body weight, mortality, and pathological changes. Moreover, after LH-C treatment, the survival rate, body weight, lung index, viral titers, bacterial colonies, pathological changes, and the inflammatory cytokines in the mouse model have all been systematically determined.

RESULTS

In the superinfection models of H1N1 and S. aureus, the mortality rate was 100% in groups of mice infected with 20 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus, 20 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus, 4 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus. The mortality rate was 50% in the group of mice infected with 4 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus. The mortality rate was 37.5% in the group of mice infected with 20 PFU/50 μL of H1N1 alone and in the group of mice infected with 2 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus. The mortality rate in the group of mice infected with 2 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus was 30%. The infected mice of 2 PFU/50 μL of H1N1 and 10 CFU/mL of S. aureus had a weight loss of nearly 10%. About the histopathological changes in the lung tissue of infection mice, severe lung lesions were found in the superinfection models. LH-C improved survival in the superinfected mice, significantly reduced lung index, lowered viral titers and bacterial loads, and alleviated lung damage. It reduced lung inflammation by down-regulating mRNA expression levels of inflammatory mediators like IL-6, IL-1β, IL-10, TNF-α, IFN-β, MCP-1, and RANTES.

CONCLUSIONS

We found that superinfection from non-lethal doses of S. aureus following non-lethal doses of H1N1 was equally fatal in mice, confirming the severity of secondary infections. The ability of LH-C to alleviate lung injury resulting from secondary S. aureus infection induced by H1N1 was confirmed. These findings provided a further assessment of LH-C, suggesting that LH-C may have good therapeutic efficacy in influenza secondary bacterial infection disease.

摘要

目的

本研究旨在建立流感病毒(H1N1)和金黄色葡萄球菌(S. aureus)二次感染的非致死剂量小鼠模型,探讨连花清瘟胶囊(LH-C)对流感病毒感染后继发细菌感染的潜在治疗作用。

方法

采用非致死剂量 H1N1 和非致死剂量 S. aureus 感染 BALB/c 小鼠,观察并记录体重、死亡率和组织病理学变化,确定病毒和细菌载量。LH-C 处理后,系统检测小鼠模型的存活率、体重、肺指数、病毒滴度、细菌载量、组织病理学变化和炎症细胞因子。

结果

在 H1N1 和 S. aureus 的双重感染模型中,20 PFU/50 μL H1N1 联合 10 CFU/mL S. aureus、20 PFU/50 μL H1N1 联合 10 CFU/mL S. aureus、4 PFU/50 μL H1N1 联合 10 CFU/mL S. aureus 感染组小鼠的死亡率为 100%;4 PFU/50 μL H1N1 联合 10 CFU/mL S. aureus 感染组小鼠的死亡率为 50%;20 PFU/50 μL H1N1 单独感染组和 2 PFU/50 μL H1N1 联合 10 CFU/mL S. aureus 感染组小鼠的死亡率为 37.5%;2 PFU/50 μL H1N1 联合 10 CFU/mL S. aureus 感染组小鼠的死亡率为 30%。20 PFU/50 μL H1N1 和 10 CFU/mL S. aureus 双重感染的感染小鼠体重减轻近 10%。肺组织的组织病理学变化显示,双重感染模型中存在严重的肺部病变。LH-C 可提高感染小鼠的存活率,显著降低肺指数,降低病毒滴度和细菌负荷,减轻肺部损伤,通过下调白细胞介素 6(IL-6)、白细胞介素 1β(IL-1β)、白细胞介素 10(IL-10)、肿瘤坏死因子-α(TNF-α)、干扰素-β(IFN-β)、单核细胞趋化蛋白 1(MCP-1)和调节激活正常 T 细胞表达和分泌因子(RANTES)等炎症介质的 mRNA 表达水平,减轻肺部炎症。

结论

本研究证实,非致死剂量 S. aureus 继发于非致死剂量 H1N1 的再次感染在小鼠中同样致命,证实了继发感染的严重性。LH-C 能减轻 H1N1 诱导的继发 S. aureus 感染引起的肺损伤,进一步评估 LH-C 可能具有良好的流感继发细菌感染疾病治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验